摘要
随着痛风和高尿酸血症发病率的逐年攀升,临床常用治疗药物(别嘌醇、苯溴马隆、非布司他等)市场销售额也逐年递增,但这些药物均存在明显的副作用,国内外药企已将研发重点放在更安全、更高效的新型降尿酸药物尿酸盐重吸收转运子1(URAT1)抑制剂领域,已上市的雷西那德在近几年备受关注,而在研新药SHR4640、SIM1909-13已处于临床试验阶段,同时用中医药治疗高尿酸血症和痛风也是未来的研究方向。对治疗痛风及高尿酸血症的药物研究进展进行综述,以期为临床用药和新药研发提供参考。
As the incidence of gout and hyperuricemia climbed annually,the market sales of allopurinol,benzbromarone and febuxostat,which are common therapeutic drugs in clinic,also increased year by year,but these drugs all have obvious side effects,and the pharmaceutical companies at home and abroad have focused their research and development on safer and efficient new urate lowering URAT1,The marketed representative drug,Lesinurad,has received much attention in recent years,while the on study drugs SHR4640 as well as SIM1909-13 are now all in clinical trials.Concomitant use of traditional Chinese medicine(TCM)for hyperuricemia and gout has also gained increasing attention.A review of the recent advances for gout and hyperuricemia will be performed to provide references for further research and applications.
作者
傅恒涛
张苗
慈小燕
崔涛
FU Hengtao;ZHANG Miao;CI Xiaoyan;CUI Tao(School of Pharmacy,North China University of Science and Technology,Tangshan 063210,China;Anhui Medical University,Hefei 230032,China;Tianjin Institute of Pharmaceutical Research,Tianjin 300301,China;Research Unit for Drug Metabolism,Chinese Academy of Medical Sciences,Beijing 100730,China)
出处
《药物评价研究》
CAS
2021年第8期1811-1816,共6页
Drug Evaluation Research
基金
中国医学科学院医学与健康科技创新工程项目(2019-I2M-5-020)
天津市“项目+团队”重点培养专项(XC202030)。
